CVX has retraced to $199.89 this week, surrendering the $205 level that featured prominently in last week's note — the first close below $200 since the early August recovery began, and a reminder that the Libya-deal bounce has not been entirely absorbed.
The pullback is not a CVX-specific story. Energy names broadly retreated, with XOM down 3%, APA off 3.7%, and OXY dropping 2.8% on the week. CVX's 2.8% decline puts it roughly in line with the peer group rather than leading it lower. The $196–$200 band that last week's note identified as new support is now being tested in real time — whether it holds into October 30 earnings is the key near-term question.
The lending market has nothing interesting to add. Short interest fell sharply, dropping nearly 19% over the week to just 0.79% of free float — among the lowest absolute readings in recent months. Borrow costs run at a negligible 0.36%, down 23% on the week. Availability is essentially unconstrained, with the lending pool effectively unlimited relative to current demand. Short sellers are not the story here; if anything, the week's drop has come with bears covering rather than pressing. Options positioning is modestly more cautious than usual — the put/call ratio is 0.72 against a 20-day average of 0.68, roughly one standard deviation above normal — but nowhere near the defensive extreme reached last week when the z-score was meaningfully higher.
The analyst picture is also consistent with last week's read, though the tone has softened slightly at the margin. Morgan Stanley remains the most recent bullish move, having raised its target to $218 last Tuesday while holding an Overweight — that view now implies roughly 9% upside from current levels, a somewhat wider gap given the stock's retreat. Barclays, by contrast, trimmed to $208 earlier in the week and holds Equal-Weight, reflecting scepticism that the recent rally fully discounts the execution risks still attached to TCO and the Hess integration. The consensus mean target is $218, and the analyst recommendation factor still ranks well above mid-field. Bulls continue to cite Kazakhstan and Permian production compounding toward a free cash flow inflection; bears flag the persistent valuation discount to ExxonMobil and lingering HES arbitration overhang as reasons the stock may underperform until those overhangs clear. CVX's dividend score ranks in the 86th percentile, and the ORTEX short score has eased to 28.5 — its lowest level in recent sessions — consistent with a name where bearish positioning is genuinely thin.
The insider activity remains notable and has, if anything, intensified. CEO Mike Wirth sold again on August 14 — a combined 317,000 shares worth roughly $63.6 million across two transactions — following smaller sales earlier in the month. Director John Hess disposed of around 300,000 shares on August 3, totalling roughly $57.6 million across four transactions. The 90-day net insider position is a net sale of approximately $302 million across all insiders. Individual transactions by executives operating under pre-arranged trading plans carry less signal than discretionary activity, and Wirth's sales appear consistent with a longer-running pattern. Still, the aggregate scale of insider supply at these price levels is worth noting alongside the broader pullback, particularly given that much of the selling occurred between $194 and $205 — the very range the stock is now revisiting.
With the $196–$200 support band now in active play and October 30 earnings still two months away, the immediate focus is whether oil price direction and the Libya production timeline provide enough near-term momentum to stabilise the tape above last week's lows.
See the live data behind this article on ORTEX.
Open CVX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
